Trial Profile
A Phase II, Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics
- Acronyms SIERRA
- Sponsors Genentech
- 11 Nov 2010 Planned end date changed from 1 May 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
- 13 Jun 2009 Results were reported at the 2009 EULAR.
- 29 Oct 2008 Actual patient numbers added.